Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ixekizumab in radiographic axial spondyloarthritis (China) – RHCH
CTR20180515Phase 3Completed
- Sponsor
- Eli Lilly and Company
- Start
- Jan 2020
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
A Phase 3 trial of ixekizumab in axial spondyloarthritis (axSpA), sponsored by Eli Lilly and Company. Started Jan 2020; status: completed.
02
Drugs
ixekizumab
03
Conditions
axial spondyloarthritis (axSpA)
Beyond the preview
Go deeper on CTR20180515.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20180515.